STX-003 / Strand Therapeutics - LARVOL DELTA

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab (clinicaltrials.gov) - P1/2 | N=220 | Recruiting | Sponsor: Strand Therapeutics Inc.

First-in-human • Monotherapy • New P1/2 trial • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

STX-003: cancer immunotherapy with systemic delivery of mRNA utilizing programmable genetic circuits for precise regulation of IL-12 expression and reduced toxicity (AACR 2025) - "These data demonstrate the potential of STX-003, our programmable RNA circuit platform, for expanding the therapeutic index of potent drugs that are limited by systemic toxicities associated with off-target expression."

IO biomarker • Breast Cancer • Melanoma • Oncology • Solid Tumor • IL12A

STX-003: A mRNA Cancer Immunotherapy Utilizing Cancer-Selective Programmable Genetic Circuits for Systemic Tumor Control (ASGCT 2025) - "Our results highlight the potential of STX-003 for treating solid tumors and the promise of programmable genetic circuits for enabling targeted expression of genetic medicines and for surmounting the problem of previously "undruggable" targets through controlled expression. Disease Focus of Abstract:Cancer Solid Tumors"

IO biomarker • Melanoma • Oncology • Solid Tumor • IL12A

Potential First-in-Class Data from Preclinical Program for STX-003, a Programmable mRNA Therapy to Treat Solid Tumor Cancers (Businesswire) - "Strand Therapeutics...will present preclinical data from its STX-003 program at the 2025 annual meetings of the American Association for Cancer Research (AACR)...and the American Society of Gene and Cell Therapy (ASGCT)....The proof-of-concept studies demonstrate that Strand’s programmable mRNA genetic circuits can target the expression of interleukin-12 (IL-12) to cancerous tissue to help achieve the right therapeutic dose while reducing off target side effects. These groundbreaking findings underscore the potential of STX-003 and build on the promise of Strand’s platform and pipeline to address the critical challenges of solid tumor immunotherapy."

Preclinical • Solid Tumor

STX-003: utilizing programmable genetic circuits for tumor-specific IL-12 expression and reduced toxicity with systemically delivered mRNA (SITC 2024) - "In healthy non-human primates, systemic administration of STX-003 demonstrated a >99% reduction in circulating IL-12 levels compared to a control without genetic circuitry. Conclusions These data demonstrate the potential of STX-003, our programmable RNA circuit platform, for the development of precision mRNA therapies for cancer."

IO biomarker • Breast Cancer • Lung Cancer • Melanoma • Oncology • Solid Tumor • IL12A

STX-003: utilizing programmable genetic circuits for tumor-specific IL-12 expression and reduced toxicity with systemically delivered mRNA (SITC 2024) - "In healthy non-human primates, systemic administration of STX-003 demonstrated a >99% reduction in circulating IL-12 levels compared to a control without genetic circuitry. Conclusions These data demonstrate the potential of STX-003, our programmable RNA circuit platform, for the development of precision mRNA therapies for cancer."

IO biomarker • Breast Cancer • Lung Cancer • Melanoma • Oncology • Solid Tumor • IL12A

STX-003: A Novel Systemically-Delivered mRNA-Based Cancer Therapy Utilizing a Programmable Genetic Circuit Platform for Tumor-Specific Protein Expression and Reduced Toxicity (ASGCT 2024) - "However, in the spleen, which is a major target organ of LNPs formulated with mRNA, mSTX-003 induces markedly lower mIL-12 levels compared to the uncircuited control. These data demonstrate the potential of our programmable RNA circuit platform for the development of precision mRNA therapies for cancer."

Oncology • Solid Tumor • IL12A